Tofacitinib

27037

Tofacitinib

Tofacitinib, also known as Tasocitinib, is a novel inhibitor of Janus kinase 3 (JAK3), a critical cytoplasmic tyrosine kinase in the signaling pathways of multiple cytokines. Research suggests Tofacitinib acts as an immunosuppressant, preventing organ transplant rejection, and that it has potential to alleviate symptoms of autoimmune diseases, such as rheumatoid arthritis and psoriasis. _x000D_

405 €

200811

Tofacitinib

435 €

10-046

Tofacitinib

Potent cell permeable JAK3 inhibitor (IC50 = 1nM). Shows also JAK-1 inhibitory activity. Immunosuppressive and anti-inflammatory agent. Inhibits signaling through heterodimeric receptors associated with JAK3, JAK1, or both of them, with functional selectivity over JAK2-paired receptors. Blocks downstream STAT signaling, resulting in potent inhibition of several cytokines, including interleukins 2, 4, 7, 9, 15 and 21, which are integral to lymphocyte activation, function and proliferation. Investigated for several autoimmune disorders including, rheumatoid arthritis and psoriasis. Potent and selective inhibitor of HIV-1 replication and virus reactivation in vitro. It is investigated against the spread of the SARS-CoV-2 (COVID-19). PRK1 inhibitor.

791.32 €

MBS5767909-5mg

(3S,4R)-Tofacitinib

1351.62 €

MBS5767909-5x5mg

(3S,4R)-Tofacitinib

5246.75 €

MBS5754179-2mg

(3S,4S)-Tofacitinib

1651.25 €